Biomedical Engineering Reference
In-Depth Information
colorectal cancer.
J Clin Oncol
2007; 25: 1658-1664. doi:10.1200/
JCO.2006.08.1620.
36. Douillard JY, Siena S, Cassidy J,
Randomized, Phase III Trial of
Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin
(FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients
With Previously Untreated Metastatic Colorectal Cancer: The PRIME
Study.
et al.
2010; 28: 4697-4705. Published on 20101004.
doi:10.1200/JCO.2009.27.4860.
37. Peeters M, Price TJ, Cervantes A,
J Clin Oncol
Randomized phase III study of
panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)
compared with FOLFIRI alone as second-line treatment in patients
with metastatic colorectal cancer.
et al.
2010; 28: 4706-4713.
Published on 20101004. doi:10.1200/JCO.2009.27.6055.
38. Giantonio BJ, Catalano PJ, Meropol NJ,
J Clin Oncol
Bevacizumab in
combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4)
for previously treated metastatic colorectal cancer: results from the
Eastern Cooperative Oncology Group Study E3200.
et al.
J Clin Oncol
2007;
25: 1539-1544. doi:10.1200/JCO.2006.09.6305.
39. Saltz LB, Clarke S, Diaz-Rubio E,
Bevacizumab in combination with
oxaliplatin-based chemotherapy as first-line therapy in metastatic
colorectal cancer: a randomized phase III study.
et al.
J Clin Oncol
2008; 26:
2013-2019. doi:10.1200/JCO.2007.14.9930.
40. Van Cutsem E, Rivera F, Berry S,
Safety and efficacy of first-line
bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines
in metastatic colorectal cancer: the BEAT study.
et al.
2009; 20:
1842-1847. Published on 20090430. doi:10.1093/annonc/mdp233.
41. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of
irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-
line treatment of metastatic colorectal cancer: updated results from
the BICC-C study.
Ann Oncol
J Clin Oncol
2008; 26: 689-690. doi:10.1200/
JCO.2007.15.5390.
42. Hurwitz H, Fehrenbacher L, Novotny W,
Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med
et al.
2004; 350: 2335-2342. doi:10.1056/NEJMoa032691.
43. Tol J, Koopman M, Cats A,
Chemotherapy, bevacizumab, and
cetuximab in metastatic colorectal cancer.
et al.
N Engl J Med
2009; 360:
563-572. doi:10.1056/NEJMoa0808268.
44. Hecht JR, Mitchell E, Chidiac T,
A randomized phase IIIB trial
of chemotherapy, bevacizumab, and panitumumab compared with
chemotherapy and bevacizumab alone for metastatic colorectal cancer.
et al.
